← @andybiotech

$AMLX

看空2022-03-28
各周期结果✓ 命中-10.5%
1d
+0.7%
5d
-6.0%
21d
-10.5%
原帖
Andy Biotech · 2022-03-28

$AMLX My quick take on FDA AdCom briefing doc Good news: No bombshell surprise. Bad news: The most appealing point of this drug to patients is the purported survival benefit, but FDA clearly doesn't buy into the claim due to multiple issues. https://t.co/phSXKsR3ig

在 X 查看 ↗